Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Identification of Genetic Variants Associated With Unexpected Infant Death Syndrome

NCT06244433 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2024-08-27
Last updated
2026-06-18

Condition(s) studied

Sudden Infant DeathSudden Unexplained Infant Death

Investigational drug(s) / intervention(s)

whole genome sequencing

whole genome sequencing: Study of all coding and non-coding sequences in the genome to identify pathogenic allelic variants

Study summary

This is a multicenter genetic study aimed at identifying new genes/variants associated with sudden infant death syndrome (SIDS) based on whole-genome sequencing of family trios

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Child Inclusion Criteria * Death of a child between 0 and 2 years of age due to sudden unexpected death in infant * Child included in the French SUDI registry with effective participation in the biocollection * Children who also meet the inclusion criteria for the BIOMINRISK-NEUROBIO (axis 2) and BIOMINRISK-RADIO-ANAT (axis 3) studies in the overall BIOMINRISK project. Parents Inclusion Criteria * Biological parents of the child included in the BIOMINRISK study * Parents who have both signed the consent form for blood collection and inclusion of their samples in the biocollection * parents beneficiaries of a social security or similar scheme Child Exclusion Criteria: * Presence of a known metabolic, genetic or syndromic pathology at the time of death Parents Exclusion Crtiteria: * Parent under guardianship * Presence of a known metabolic, genetic or syndromic pathology

Primary outcome measure(s)

  • Identification of genetic variants — up to 38 months
    Presence of de novo genetic point mutations in coding and non-coding sequences, based on analysis of family trios using a whole-genome sequencing approach

Trial sites (18)

FacilityCityRegionStatus
Nantes University Hospital Nantes Loire-Atlantique Recruiting
CHU Amiens Amiens France Recruiting
CHU Angers Angers France Recruiting
CHU Besançon Besançon France Recruiting
APHP - Hôpital Jean Verdier Bondy France Recruiting
CHU Brest Brest France Recruiting
CHU de Caen-Normandie Caen France Not Yet Recruiting
APHP - Hôpital Antoine Béclère Clamart France Recruiting
Centre Hospitalier Sud Francilien Corbeil-Essonnes France Not Yet Recruiting
CHU Grenoble Grenoble France Recruiting
HCL Lyon France Recruiting
AP-HM Marseille France Not Yet Recruiting
CHU Montpellier Montpellier France Recruiting
CHRU Nancy Nancy France Recruiting
CHU de Poitiers Poitiers France Not Yet Recruiting
CHU Rouen Rouen France Recruiting
CHU Saint Etienne Saint-Etienne France Recruiting
CHU Toulouse Toulouse France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06244433 on ClinicalTrials.gov ↗ ← All trials in France